Search

Author/Creator Buhl, Derek L.

1. Pharmacological evaluation of clinically relevant concentrations of (2R, 6R)-hydroxynorketamine. (15th July 2019)

Authors:
Shaffer, Christopher L.; Dutra, Jason K.; Tseng, Wei Chou; Weber, Mark L.; Bogart, Luke J.; Hales, Katherine; Pang, Jincheng; Volfson, Dmitri; am Ende, Christopher W.; Green, Michael E.; Buhl, Derek L.
Journal:
Neuropharmacology
Issue:
Volume 153(2019)
Page Start:
73
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Pronounced antiepileptic activity of the subtype‐selective GABAA‐positive allosteric modulator PF‐06372865 in the GAERS absence epilepsy model. (12th August 2018)

Authors:
Duveau, Venceslas; Buhl, Derek L.; Evrard, Alexis; Ruggiero, Céline; Mandé‐Niedergang, Betty; Roucard, Corinne; Gurrell, Rachel
Journal:
CNS neuroscience & therapeutics
Issue:
Volume 25:Number 2(2019)
Page Start:
255
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Safety, pharmacokinetics and quantitative EEG modulation of TAK‐071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects. Issue 2 (31st July 2021)

Authors:
Yin, Wei; Mamashli, Fahimeh; Buhl, Derek L.; Khudyakov, Polyna; Volfson, Dmitri; Martenyi, Ferenc; Gevorkyan, Hakop; Rosen, Laura; Simen, Arthur A.
Journal:
British journal of clinical pharmacology
Issue:
Volume 88:Issue 2(2022)
Page Start:
600
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗